MYBL2 maintains stemness and promotes theta-mediated end joining in triple negative breast cancer
Rachel Bayley, Anna Munsey, Suman Ahmed, Ciara M. Ward, Amber Stiby, Bohdana-Myroslava Briantseva, Kirendeep Jawanda, Abeer M. Shaaban, Marco Saponaro, Graeme C.M. Smith, Robert B. Clarke, Clare C. Davies, Paloma García
This study shows MYBL2 maintains stemness and promotes theta-mediated end joining in TNBC, and identifies Pol{theta}/ATR inhibition as a therapeutic strategy.
bioRxiv · Apr 15, 2025 · PreprintCancer Biology